Larimar Therapeutics, Inc. (LRMR) Misses Q3 EPS by 20c
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Join SI Premium – FREE
Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.61), $0.20 worse than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pizza Hut CEO Aaron Powell resigns
- Albany International ends strategic review, keeps Salt Lake City facility
- Citi Downgrades Pearson PLC (PSON:LN) (PSO) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
